Trifluoroacetic acid → [7-(2-Butynyl)-2,6-dioxo-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] acetic acid methyl ester trifluoroacetate
反応式
C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[N:22]([CH2:23][C:24]#[C:25][CH3:26])[C:21]3[C:20](=[O:27])[NH:19][C:18](=[O:28])[N:17]([CH2:29][C:30]([O:32][CH3:33])=[O:31])[C:16]=3[N:15]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.[F:34][C:35]([F:40])([F:39])[C:36]([OH:38])=[O:37]>>[F:34][C:35]([F:40])([F:39])[C:36]([OH:38])=[O:37].[CH3:33][O:32][C:30](=[O:31])[CH2:29][N:17]1[C:16]2[N:15]=[C:14]([N:11]3[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]3)[N:22]([CH2:23][C:24]#[C:25][CH3:26])[C:21]=2[C:20](=[O:27])[NH:19][C:18]1=[O:28]参加物
3
反応物 2
生成物 1
実験手順
4-[7-(2-Butynyl)-3-methoxycarbonylmethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl]piperazine-1-carboxylic acid tert-butyl ester (13 mg) was dissolved in trifluoroacetic acid (0.5 ml), and the solution was stirred at room temperature for 30 minutes. After the solvent was removed by distillation, a half of the residue was purified by HPLC with a reversed phase system column using water-acetonitrile-trifluoroacetic acid system as elution solvent to give 2.4 mg of the title compound.
後処理
- customAfter the solvent was removed by distillation
- customa half of the residue was purified by HPLC with a reversed phase system column
- washas elution solvent
出典と根拠
- ORDレコード
- ord-d474136064c3418089ffd13c09f942de
- 出典データセット
- uspto-grants-2006_07
- 特許番号
- US07074798B2
反応ノート
読み込み中…